Wedbush Reaffirms Outperform Rating for Keros Therapeutics (NASDAQ:KROS)

Wedbush reiterated their outperform rating on shares of Keros Therapeutics (NASDAQ:KROS) in a report released on Thursday,RTT News reports. The firm currently has a $84.00 price objective on the stock. Wedbush also issued estimates for Keros Therapeutics’ Q3 2024 earnings at ($1.31) EPS, Q4 2024 earnings at ($1.36) EPS, FY2024 earnings at ($5.14) EPS, Q1 2025 earnings at ($1.41) EPS, Q2 2025 earnings at ($1.43) EPS, Q3 2025 earnings at ($1.25) EPS, Q4 2025 earnings at ($1.27) EPS, FY2025 earnings at ($5.32) EPS, FY2026 earnings at ($5.16) EPS, FY2027 earnings at ($5.57) EPS and FY2028 earnings at ($4.66) EPS.

Other research analysts have also recently issued reports about the company. Scotiabank initiated coverage on Keros Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Keros Therapeutics in a research report on Thursday. Guggenheim assumed coverage on shares of Keros Therapeutics in a report on Monday, September 23rd. They issued a “buy” rating and a $96.00 price objective on the stock. Jefferies Financial Group started coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating for the company. Finally, Cantor Fitzgerald assumed coverage on shares of Keros Therapeutics in a research note on Thursday, October 24th. They issued an “overweight” rating on the stock. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $88.89.

Keros Therapeutics Stock Performance

NASDAQ:KROS traded up $0.74 on Thursday, reaching $67.91. The company’s stock had a trading volume of 624,526 shares, compared to its average volume of 336,103. Keros Therapeutics has a 1-year low of $27.31 and a 1-year high of $73.00. The business’s 50-day moving average price is $58.19 and its two-hundred day moving average price is $52.16. The firm has a market cap of $2.55 billion, a PE ratio of -13.03 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The business had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 45.13% and a negative net margin of 27,890.94%. The business’s quarterly revenue was up 4750.0% compared to the same quarter last year. During the same period last year, the firm posted ($1.33) earnings per share. As a group, sell-side analysts expect that Keros Therapeutics will post -4.93 EPS for the current year.

Insider Activity

In other Keros Therapeutics news, Director Carl L. Gordon sold 250,000 shares of Keros Therapeutics stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the completion of the sale, the director now owns 119,522 shares in the company, valued at $5,260,163.22. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 22.90% of the stock is currently owned by company insiders.

Institutional Trading of Keros Therapeutics

Several large investors have recently modified their holdings of KROS. Price T Rowe Associates Inc. MD lifted its position in Keros Therapeutics by 17.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock worth $80,666,000 after purchasing an additional 176,803 shares during the period. Assenagon Asset Management S.A. bought a new stake in Keros Therapeutics during the 2nd quarter worth $1,118,000. Bank of New York Mellon Corp increased its holdings in Keros Therapeutics by 18.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock worth $5,410,000 after purchasing an additional 18,755 shares in the last quarter. Swiss National Bank boosted its stake in shares of Keros Therapeutics by 22.0% during the first quarter. Swiss National Bank now owns 49,900 shares of the company’s stock valued at $3,303,000 after purchasing an additional 9,000 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Keros Therapeutics in the second quarter valued at approximately $532,000. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.